摘要
目的探讨两种不同血液透析方案下终末期肾病(end stage renal disease,ESRD)患者治疗前后T淋巴细胞亚群线粒体参数变化。方法选取2021年9月至2022年2月期间在武汉科技大学附属普仁医院行规律透析的ESRD患者为研究对象,经过纳入、排除标准筛选出符合要求的患者100例。采用随机数字表法将100例患者随机分为对照组、观察组各50例。观察治疗前及治疗6个月后两组患者T淋巴细胞(CD3^(+)细胞,CD4^(+)细胞,CD8^(+)细胞)细胞绝对计数及百分比、CD4^(+)/CD8^(+)比值、线粒体质量(mitochondrial mass,MM)及线粒体损伤指数(mitochondrial damage index,MDI)变化。结果治疗前两组患者T淋巴细胞亚群计数、百分比及MM、MDL差异无统计学意义(P>0.05)。治疗后观察组CD4^(+)百分比为(39.71±12.96)%,对照组CD4^(+)百分比为(33.53±7.13)%,观察组高于对照组(P<0.05);治疗后观察组CD4^(+)/CD8^(+)为(2.27±0.63),对照组CD4^(+)/CD8^(+)为(1.39±0.56),观察组高于对照组(P<0.05);治疗后观察组CD3^(+)MDI为72.43,对照组CD3^(+)MDI为118.21,观察组低于对照组(P<0.05);治疗后观察组CD4^(+)MDI为123.70,对照组CD4^(+)MDI为332.21,观察组低于对照组(P<0.05);治疗后观察组CD8^(+)MDI为180.74,对照组CD8^(+)MDI为312.33(P<0.05),观察组低于对照组。对照组治疗前CD4^(+)百分比为(28.56±6.28)%,治疗后为(33.53±7.13)%,治疗后大于治疗前(P<0.05);对照组治疗前CD4^(+)/CD8^(+)为(1.25±0.53),治疗后CD4^(+)/CD8^(+)为(1.39±0.56),治疗后大于治疗前(P<0.05);对照组CD3^(+)细胞绝对计数治疗前为(538.99±254.18),治疗后为(556.37±275.78),治疗后大于治疗前(P<0.05);对照组CD3^(+)MM治疗前为(143391.84±37879.02),治疗后为(145307.76±35485.05),治疗后大于治疗前(P<0.05);对照组CD3^(+)MDI治疗前为137.29,治疗后为118.21,治疗后小于治疗前(P<0.05);对照组CD4^(+)MDI治疗前为397.67,治疗后为332.21,治疗后小于治疗前(P<0.05);对照组CD8^(+)MDI治疗前为335.63,�
Objective To explore the changes of mitochondrial parameters of T lymphocyte subsets in patients with end-stage renal disease(ESRD)before and after treatment under two different hemodialytic schemes.Methods From September 2021 to February 2022,100 ESRD patients undergoing regular dialysis were selected as study subjects.They were randomized into two groups of control and observation(n=50 each).Absolute count and percentage of T lymphocytes(CD3^(+),CD4^(+),CD8^(+)),CD4^(+)/CD8^(+)ratio,mitochondrial mass(MM)and mitochondrial damage index(MDI)were observed before and after 6-month treatment.Results No significant inter-group difference existed in T count/percentage of lymphocyte subgroup,MM or MDI pre-treatment(P>0.05).In observation group,CD4^(+)%[(39.71±12.96)%vs(33.53±7.13)%,P<0.05]and CD4^(+)/CD8^(+)[(2.27±0.63)vs(1.39±0.56),P<0.05]decreased while CD3^(+)MDI(72.43 vs 118.21,P<0.05),CD4^(+)MDI(123.70 vs 332.21,P<0.05)and(180.74 vs 312.33,P<0.05)increased after treatment.In control group,CD4^(+)%[(28.56±6.28)%vs(33.53±7.13)%,P<0.05];CD4^(+)/CD8^(+)[(1.25±0.53)vs(1.39±0.56),P<0.05],absolute count of CD3^(+)[(538.99±254.18)vs(556.37±275.78),P<0.05]and CD3^(+)MM rose[(143391.84±37879.02)vs(145307.76±35485.05),P<0.05]while CD3^(+)MDI(137.29 vs 118.21,P<0.05),CD4^(+)MDI(397.67 vs 332.21,P<0.05)and CD8^(+)MDI declined(335.63 vs 312.33,P<0.05].In observation group,CD3^(+)count[(685.60±271.32)vs(895.67±351.42),P<0.05],CD4^(+)count[(295.53±198.60)vs(585.67±261.86),P<0.05],CD3^(+)%[(51.43±12.15)%vs(58.25±14.99)%,P<0.05],CD4^(+)%[(30.53±12.41)%vs(39.71±12.96)%,P<0.05],CD4^(+)/CD8^(+)[(1.57±0.60)vs(2.27±0.63),P<0.05],CD3^(+)MM(147886.07±55841.38)vs(152638.22±49675.75),P<0.05],CD4^(+)MM[(163490.80±64714.31)vs(165679.79±68484.85),P<0.05]and CD8^(+)MM spiked[(125774.47±46354.09)vs(129638.64±42896.53),P<0.05]while CD3^(+)MDI(139.75 vs 72.43,P<0.05),CD4^(+)MDI(203.73 vs 123.70,P<0.05)and CD8^(+)MDI dropped(267.33 vs 180.74,P<0.05).Conclusion Both hemodialysis and hemodialysis plus hemoperfusion may red
作者
陈景
唐小铁
郭鹏
杨昊陇
Chen Jing;Tang Xiao-tie;Guo Peng;Yang Hao-long(Affiliated Puren Hospital,Wuhan University of Science&Technology,Wuhan 430080,China)
出处
《临床肾脏病杂志》
2023年第12期1002-1009,共8页
Journal Of Clinical Nephrology
基金
湖北省联合基金项目(WJ2018H0107)。
关键词
血液透析
血液灌流
终末期肾病
T细胞亚群
Hemodialysis
Hemoperfusion
End-stage renal disease
T cell subpopulation
